GF-TRIPLE 50mg

For research use only — not for human or veterinary use.

Analytical Verification (COA)

Each batch of GF-Triple supplied by Grail Formula undergoes independent third-party laboratory verification to confirm compound identity, assay content, purity and microbiological safety.

Analytical testing for this batch was performed by Liquilabs s.r.o. (Czechia) using validated chromatographic and spectrometric techniques.

Batch: GF_TRIPLE50_B242

Key analytical results include:

• Assay Content: 47.78 mg
• Identification – Retention Time: 1.00
• Identification – Spectrum: 999
• Purity: greater than 99.8 percent
• Bacterial Endotoxins: below 0.001 EU per mg
• Total Aerobic Microbial Count: not detected
• Total Yeast and Mold Count: not detected

Independent heavy metal screening confirmed no detectable levels of arsenic, cadmium, cobalt, lead, nickel, mercury or vanadium.

These analytical procedures ensure traceability, purity verification and laboratory-grade compound consistency.

Product Overview

GF-Triple is a peptide research compound based on the molecule GF-TRIPLE, frequently studied in controlled laboratory environments focused on receptor-mediated metabolic signalling pathways.

The compound belongs to a class of multi-receptor peptide agonists investigated in biochemical research for their interaction with metabolic regulatory signalling systems.

This preparation contains 50 mg of high purity lyophilized peptide supplied in a sealed research vial. The lyophilization process preserves peptide stability and allows researchers to reconstitute the compound for controlled in vitro experimentation.

Because of its defined peptide structure and stable analytical profile, GF-Triple has become a frequently referenced compound in experimental metabolic signalling research.

Compound Overview

GF-Triple contains GF-TRIPLE, a synthetic peptide studied in biochemical research for its interaction with multiple receptor systems involved in metabolic regulation.

Within experimental models, the compound is commonly examined for its interaction with glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptor signalling pathways.

Due to this multi-receptor interaction profile, GF-TRIPLE is frequently studied in laboratory settings investigating metabolic signalling networks and receptor-mediated regulatory processes.

Historical Background and Scientific Context

Research into metabolic signalling peptides expanded rapidly during the early twenty-first century as scientists identified a growing number of receptor systems involved in metabolic regulation.

During this period, peptide compounds capable of interacting with multiple receptor pathways began to receive significant attention in laboratory research.

GF-TRIPLE emerged as one of the experimental peptides studied for its ability to interact with several metabolic signalling receptors simultaneously.

Mechanistic Focus in Research

Within experimental laboratory settings, GF-Triple is commonly studied in relation to receptor-mediated metabolic signalling pathways.

Research investigations commonly explore the compound in experimental models examining:

• GLP-1 receptor signalling pathways
• GIP receptor interaction dynamics
• Glucagon receptor signalling systems
• Multi-receptor peptide interaction models
• Metabolic signalling pathway analysis
• Comparative receptor activation research
• Intracellular metabolic regulatory networks

These experimental models allow scientists to investigate molecular signalling mechanisms involved in metabolic regulation and peptide-mediated receptor interaction.

Research Applications

In controlled research environments, GF-Triple may be utilised in experimental models designed to explore receptor-mediated metabolic signalling and peptide interaction networks.

Examples of research applications include:

• Metabolic signalling pathway investigation
• Peptide receptor interaction research
• Intracellular metabolic network modelling
• Comparative peptide compound evaluation
• Receptor activation pathway analysis
• Multi-receptor signalling research
• Controlled in vitro metabolic signalling studies

Grail Formula Quality

Every Grail Formula research compound is produced under strict quality control procedures designed to support reliable laboratory experimentation.

Each batch undergoes independent analytical testing to verify:

• Compound identity
• Assay accuracy
• Purity confirmation
• Microbial safety
• Endotoxin levels
• Heavy metal screening
• Full batch traceability

All testing is performed by independent laboratories to ensure transparent verification and reproducible research material.

Research Use Limitation

• Used solely for in vitro experiments
• Not permitted for clinical trials involving humans
• Not permitted for human or veterinary administration
• Not permitted for investigational human use

Independently verified by Liquilabs s.r.o. (Czechia)
Validated assay content 52.43 mg
Purity greater than 99.8 percent
Retention time and spectral identity confirmation
Endotoxin levels below 0.001 EU per mg
No detectable microbial contamination
No detectable heavy metals
For research use only — not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.